Get Rid Of Your Allergies And Asthma Using A Tiny Amount Under The Tongue

Pollen from a variety of common plants: sunflo...
Pollen from a variety of common plants: sunflower (Helianthus annuus), morning glory Ipomoea purpurea, hollyhock (Sildalcea malviflora), lily (Lilium auratum), primrose (Oenothera fruticosa) and castor bean (Ricinus communis). The image is magnified some x500, so the bean shaped grain in the bottom left corner is about 50 μm long. (Photo credit: Wikipedia)

The long term is “sublingual immunotherapy” but the short version is that you take a tiny amount of the allergic substance under the tongue.

Rather than being foolish, the idea follows a certain logic. Most of us are not allergic to everything we eat. Somehow the body differentiates between something you swallow and something that gets up your nose. So why not use that same process to desensitize yourself to allergens?

Welcome to the wonderful world of homeopathic allergens. Unlike the standard model, these things are so diluted they wouldn’t show up on a water test. Gradually walking backward from that level of dilution should be a way to avoid allergic response. It also avoids the multiple shots of allergists.

But do we have any data? Here’s the short New York Times article on the JAMA study of 63 different randomized trials. The answer is 40% improvement over placebo, without any life threatening events.

But don’t stop there, here’s the JAMA abstract:

JAMA. 2013 Mar 27;309(12):1278-88. doi: 10.1001/jama.2013.2049.

Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review.


Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.



Allergic rhinitis affects up to 40% of the US population. To desensitize allergic individuals, subcutaneous injection immunotherapy or sublingual immunotherapy may be administered. In the United States, sublingual immunotherapy is not approved by the Food and Drug Administration. However, some US physicians use aqueous allergens, off-label, for sublingual desensitization.


To systematically review the effectiveness and safety of aqueous sublingual immunotherapy for allergic rhinoconjunctivitis and asthma.


The databases of MEDLINE, EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials were searched through December 22, 2012. English-language randomized controlled trials were included if they compared sublingual immunotherapy with placebo, pharmacotherapy, or other sublingual immunotherapy regimens and reported clinical outcomes. Studies of sublingual immunotherapy that are unavailable in the United States and for which a related immunotherapy is unavailable in the United States were excluded. Paired reviewers selected articles and extracted the data. The strength of the evidence for each comparison and outcome was graded based on the risk of bias (scored on allocation, concealment of intervention, incomplete data, sponsor company involvement, and other bias), consistency, magnitude of effect, and the directness of the evidence.


Sixty-three studies with 5131 participants met the inclusion criteria. Participants’ ages ranged from 4 to 74 years. Twenty studies (n = 1814 patients) enrolled only children. The risk of bias was medium in 43 studies (68%). Strong evidence supports that sublingual immunotherapy improves asthma symptoms, with 8 of 13 studies reporting greater than 40% improvement vs the comparator. Moderate evidence supports that sublingual immunotherapy use decreases rhinitis or rhinoconjunctivitis symptoms, with 9 of 36 studies demonstrating greater than 40% improvement vs the comparator. Medication use for asthma and allergies decreased by more than 40% in 16 of 41 studies of sublingual immunotherapy with moderate grade evidence. Moderate evidence supports that sublingual immunotherapy improves conjunctivitis symptoms (13 studies), combined symptom and medication scores (20 studies), and disease-specific quality of life (8 studies). Local reactions were frequent, but anaphylaxis was not reported.


The overall evidence provides a moderate grade level of evidence to support the effectiveness of sublingual immunotherapy for the treatment of allergic rhinitis and asthma, but high-quality studies are still needed to answer questions regarding optimal dosing strategies. There were limitations in the standardization of adverse events reporting, but no life-threatening adverse events were noted in this review.


Tell me what you think!

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.